GALT Galectin Therapeutics Inc.

-0.12  -3%
Previous Close 4.3
Open 4.3
Price To Book -104.5
Market Cap 190399945
Shares 45,550,226
Volume 189,721
Short Ratio
Av. Daily Volume 423,709

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated during fall of 2019.
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 1b data released September 20, 2018. ORR 50%.
GR-MD-02 and pembrolizumab (KEYTRUDA)
Phase 2a interim data released May 2016
moderate-to-severe plaque psoriasis.

Latest News

  1. Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement
  2. Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
  3. Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
  4. Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248%
  5. Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
  6. Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
  7. Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
  8. Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings
  9. Galectin Therapeutics to Present at Berenberg NASH Day in New York
  10. Conatus (CNAT) Completes Enrollment in Phase II NASH Study
  11. Ascendis Pharma Files IND for Hypoparathyroidism Candidate
  12. Alkermes Sinks as FDA Refuses to Approve Depression Drug
  13. AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA
  14. Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year?
  15. Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
  16. Did Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Sell Shares?
  17. Galectin Therapeutics Announces Extension of $10 Million Line Credit
  18. New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  19. Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
  20. Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update